title: Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.
abstract: Tumor differentiation enhances morphologic and microvascular heterogeneity fostering hypoxia that retards intratumoral drug delivery, distribution, and compromise therapeutic efficacy. In this study, the influence of tumor biologic heterogeneity on the interaction between cytotoxic chemotherapy and selenium was examined using a panel of human tumor xenografts representing cancers of the head and neck and lung along with tissue microarray analysis of human surgical samples. Tumor differentiation status, microvessel density, interstitial fluid pressure, vascular phenotype, and drug delivery were correlated with the degree of enhancement of chemotherapeutic efficacy by selenium. Marked potentiation of antitumor activity was observed in H69 tumors that exhibited a well-vascularized, poorly differentiated phenotype. In comparison, modulation of chemotherapeutic efficacy by antiangiogenic selenium was generally lower or absent in well-differentiated tumors with multiple avascular hypoxic, differentiated regions. Tumor histomorphologic heterogeneity was found prevalent in the clinical samples studied and represents a primary and critical physiological barrier to chemotherapy.
authors.affiliation: Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Youcef M
authors.initials: YM
authors.lastname: Rustum
authors.forename: Károly
authors.initials: K
authors.lastname: Tóth
authors.forename: Mukund
authors.initials: M
authors.lastname: Seshadri
authors.forename: Arindam
authors.initials: A
authors.lastname: Sen
authors.forename: Farukh A
authors.initials: FA
authors.lastname: Durrani
authors.forename: Emily
authors.initials: E
authors.lastname: Stott
authors.forename: Carl D
authors.initials: CD
authors.lastname: Morrison
authors.forename: Shousong
authors.initials: S
authors.lastname: Cao
authors.forename: Arup
authors.initials: A
authors.lastname: Bhattacharya
references.citation: Neoplasia. 2008 Aug;10(8):857-65
references.pmid: 18670644
references.citation: Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911
references.pmid: 20066420
references.citation: Br J Nutr. 2004 Jan;91(1):11-28
references.pmid: 14748935
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):718-26
references.pmid: 18827575
references.citation: Oncogene. 2006 Apr 20;25(17):2509-19
references.pmid: 16518418
references.citation: J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
references.pmid: 17895480
references.citation: Clin Cancer Res. 2004 Feb 1;10(3):1121-9
references.pmid: 14871992
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):97-103
references.pmid: 17056201
references.citation: Clin Colorectal Cancer. 2009 Jul;8(3):155-62
references.pmid: 19632930
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7220-5
references.pmid: 16243791
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Microvasc Res. 2005 Jul;70(1-2):116-20
references.pmid: 16137719
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5666-74
references.pmid: 14654550
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2561-9
references.pmid: 15073137
references.citation: Magn Reson Med. 1997 Feb;37(2):236-42
references.pmid: 9001148
references.citation: J Clin Oncol. 1991 Jan;9(1):50-61
references.pmid: 1702146
references.citation: Neoplasia. 2006 Jul;8(7):534-42
references.pmid: 16867215
references.citation: Nat Med. 2001 Sep;7(9):987-9
references.pmid: 11533692
references.citation: Nat Rev Cancer. 2004 Oct;4(10):806-13
references.pmid: 15510161
references.citation: Nat Rev Cancer. 2007 Jun;7(6):475-85
references.pmid: 17522716
references.citation: Biochim Biophys Acta. 2009 Apr;1795(2):162-72
references.pmid: 19344680
references.citation: Int J Cancer. 2004 Nov 20;112(4):570-6
references.pmid: 15382037
references.citation: Cancer Chemother Pharmacol. 2008 Aug;62(3):499-508
references.pmid: 17989978
references.citation: Clin Cancer Res. 2004 Dec 1;10(23):8005-17
references.pmid: 15585636
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3926-32
references.pmid: 18559614
references.citation: Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):375-81
references.pmid: 20216402
references.citation: Nat Clin Pract Oncol. 2009 Jan;6(1):43-52
references.pmid: 18982000
references.citation: Nature. 2009 Mar 19;458(7236):290-2
references.pmid: 19295595
references.citation: Cancer Res. 1993 May 15;53(10 Suppl):2204-7
references.pmid: 8485703